UBS Group
SIOX

UBS Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

UBS Group’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-45,838
Closed -$2.52M – 8192
2017
Q3 		$2.52M Buy
+45,838
New +$7.73M ﹤0.01% 2911

Other funds holding SIOX

JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

UBS Group's SIOX Position: Q1 2023 in Review

UBS Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 80,100 shares — an estimated $35.2K sold.

UBS Group first reported a position in SIOX in Q3 2015 and held it in 25 quarters. The position peaked at $254K in Q4 2017. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

  • UBS Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 80,100 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $35.2K.
  • UBS Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 25 quarters.
  • UBS Group's Sio Gene Therapies Inc. Common Stock position peaked at $254K in Q4 2017.
  • 4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.